All In Biotech

NDA 020075 · Amneal

Lioresal

Baclofen · Intrathecal · gamma-Aminobutyric Acid-ergic Agonist

Priority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Dec 13, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

Jun 17, 1992

Approved uses

2

Original approval plus efficacy supplements

Registered trials

123

30 Phase 3, 6 recruiting

FAERS reports

85,287

56,425 serious, 6,381 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

Abrupt discontinuation of intrathecal baclofen, regardless of the cause, has resulted in sequelae that include high fever, altered mental status, exaggerated rebound spasticity, and muscle rigidity, that in rare cases has advanced to rhabdomyolysis, multiple organ-system failure and death. Prevention of abrupt discontinuation of intrathecal baclofen requires careful attention to programming and monitoring of the infusion system, refill scheduling and procedures, and pump alarms. Patients and caregivers should be advised of the importance of keeping scheduled refill visits and should be educated on the early symptoms of baclofen withdrawal. Special attention should be given to patients at apparent risk (e.g. spinal cord injuries at T-6 or above, communication difficulties, history of withdrawal symptoms from oral or intrathecal baclofen). Consult the technical manual of the implantable...

What it is approved for

From the label in effect Dec 9, 2022.

INDICATIONS AND USAGE LIORESAL INTRATHECAL (baclofen injection) is indicated for use in the management of severe spasticity. Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion of LIORESAL INTRATHECAL via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. LIORESAL INTRATHECAL is intended for use by the intrathecal route in single bolus test doses (via spinal catheter or lumbar puncture) and, for chronic use, only in implantable pumps approved by the FDA specifically for the administration of LIORESAL INTRATHECAL into the intrathecal space. Spasticity of Spinal Cord Origin: Evidence supporting the efficacy of LIORESAL INTRATHECAL was obtained in randomized, controlled investigations that compared the effects of either a single intrathecal dose or a three day intrathecal infusion of LIORESAL INTRATHECAL to placebo in patients with severe spasticity and spasms due to either spinal cord trauma or multiple sclerosis. LIORESAL INTRATHECAL was superior to placebo on both principal outcome measures employed: change from baseline in the Ashworth rating of spasticity and the frequency of spasms. Spasticity of Cerebral Origin: The efficacy of LIORESAL INTRATHECAL was investigated in three controlled clinical trials; two enrolled patients with cerebral palsy and one enrolled patients with spasticity due to previous brain injury. The first study, a randomized...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 14, 1996 Supplement 4 · Efficacy
  • Jun 17, 1992 Original approval · Type 3 - New Dosage Form · priority review
3 products under this application
  • LIORESAL · BACLOFEN 0.05MG/ML · INJECTABLE, INTRATHECAL · Prescription · TE AP
  • LIORESAL · BACLOFEN 0.5MG/ML · INJECTABLE, INTRATHECAL · Prescription · TE AP
  • LIORESAL · BACLOFEN 2MG/ML · INJECTABLE, INTRATHECAL · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Baclofen" as an intervention, any sponsor and status, largest first.

All 123 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue6,308
  • drug ineffective5,651
  • pain5,558
  • fall5,455
  • nausea4,695
  • headache4,449
  • gait disturbance4,137
  • off label use3,870
  • dizziness3,632
  • urinary tract infection3,527
  • asthenia3,445
  • multiple sclerosis relapse3,424

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004646
2005757
2006675
2007795
2008886
20091,033
20101,500
20111,741
20122,516
20133,027
20144,252
20155,157
20167,596
20177,024
20187,705
20196,672
20205,778
20215,486
20225,099
20235,673
20244,226
20254,065
20262,975

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 565 on PubMed

Sponsor: Amneal

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.